Cited by 1,557Lipoproteins and Cardiovascular HealthCancer, Lipids, and MetabolismAcute Myocardial Infarction Research

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events

Open access

Ridker, Paul M., Rifai, Nader, Clearfield, Michael, Downs, John R., Weis, Stephen E., Miles, J. Shawn, Gotto, Antonio M.·2001·New England Journal of Medicine

DOI 10.1056/nejm200106283442601

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Elevated levels of C-reactive protein, even in the absence of hyperlipidemia, are associated with an increased risk of coronary events. Statin therapy reduces the level of C-reactive protein independently of its effect on lipid levels. We hypothesized that statins might prevent coronary events in persons with elevated C-reactive protein levels who did not have overt hyperlipidemia. METHODS: The level of C-reactive protein was measured at base line and after one year in 5742 participants in a five-year randomized trial of lovastatin for the primary prevention of acute coronary events. RESULTS: The rates of coronary events increased significantly with increases in the base-line levels of C-reactive protein. Lovastatin therapy reduced the C-reactive protein level by 14.8 percent (P<0.001), an effect not explained by lovastatin-induced changes in the lipid profile. As expected, lovastatin was effective in preventing coronary events in participants whose base-line ratio of total cholesterol to high-density lipoprotein (HDL) cholesterol was higher than the median ratio, regardless of the level of C-reactive protein (number needed to treat for five years to prevent 1 event, 47; P=0.005). However, lovastatin was also effective among those with a ratio of total to HDL cholesterol that was lower than the median and a C-reactive protein level higher than the median (number needed to treat, 43; P=0.02). In contrast, lovastatin was ineffective among participants with a ratio of total to HDL cholesterol and a C-reactive protein level that were both lower than the median (number needed to treat, 983; P=0.80). CONCLUSIONS: Statin therapy may be effective in the primary prevention of coronary events among subjects with relatively low lipid levels but with elevated levels of C-reactive protein.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm200106283442601

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
Ridker, P. M., Hennekens, C. H., Buring, J. E., & Rifai, N. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003233421202 · Cited by 5,850
Self-citation
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Self-citation
Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Self-citation
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Elevated C-reactive protein levels in overweight and obese adults
Visser, M. (1999) · JAMA · doi:10.1001/jama.282.22.2131 · Cited by 2,494
Molecular Bases of the Acute Coronary Syndromes
Libby, P. (1995) · Circulation · doi:10.1161/01.cir.91.11.2844 · Cited by 2,029
C-Reactive Protein, a Sensitive Marker of Inflammation, Predicts Future Risk of Coronary Heart Disease in Initially Healthy Middle-Aged Men
Köenig, W., Sund, M., Fröhlich, M., Fischer, H.-G., Löwel, H., Döring, A., Hutchinson, W. L., & Pepys, M. B. (1999) · Circulation · doi:10.1161/01.cir.99.2.237 · Cited by 1,952

Show all 27 references

Sorted by citations

Items 901–998 of 998

PON1, A New Biomarker of Cardiovascular Disease, Is Low in Patients with Systemic Vasculitis
Quéméneur, T., Martin‐Nizard, F., Kandoussi, A., Kyndt, X., Vanhille, P., HACHULLA, E., Hatron, P., Fruchart, J., Duriez, P., & Lambert, M. (2007) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2007.03.002 · Cited by 16
Chronic immune stimulation as a contributing cause of chronic disease in opiate addiction including multi-system ageing
Reece, A. S. (2010) · Medical Hypotheses · doi:10.1016/j.mehy.2010.07.047 · Cited by 17
High-sensitivity C-reactive protein and clopidogrel treatment in patients at high risk of cardiovascular events: a substudy from the CHARISMA trial
Weber, M. W., Bhatt, D. L., Brennan, D. M., Hankey, G. J., Steinhubl, S. R., Johnston, S. C., Montalescot, G., Mak, K.-H., Fox, K. A. A., Easton, D., et al. (2011) · Heart · doi:10.1136/hrt.2010.210419 · Cited by 16
Rosuvastatin prevents pressure overload-induced myocardial hypertrophy via inactivation of the Akt, ERK1/2 and GATA4 signaling pathways in rats
Xu, X., Zhang, L., & Liang, J. (2013) · Molecular Medicine Reports · doi:10.3892/mmr.2013.1548 · Cited by 16
Therapeutic Options to Further Lower C-Reactive Protein for Patients on Statin Treatment
Joshi, P. H., & Jacobson, T. A. (2010) · Current Atherosclerosis Reports · doi:10.1007/s11883-009-0075-x · Cited by 16
Statins and other agents for vascular inflammation
Owens, C. D. (2012) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2012.08.045 · Cited by 16
Assessment of serum leptin, pregnancy-associated plasma protein A and CRP levels as indicators of plaque vulnerability in patients with acute coronary syndrome
Lodh, M., Goswami, B., Parida, A. K., Patra, S. K., & Saxena, A. (2012) · Cardiovascular journal of South Africa/Cardiovascular journal of Southern Africa · doi:10.5830/cvja-2012-008 · Cited by 16
Focusing on Inflammation in the Treatment of Atherosclerosis
Call, J. T., Deliargyris, E., & Newby, L. K. (2004) · Cardiology in Review · doi:10.1097/01.crd.0000111822.34362.71 · Cited by 16
Evaluation of diagnostic relevance of mRNA levels in peripheral blood: predictive value for mortality in hemodialysis patients
Füth, R. (2004) · Cytokine · doi:10.1016/j.cyto.2004.05.006 · Cited by 16
Pathophysiological roles and clinical importance of biomarkers in acute coronary syndrome.
Chan, C., & Rainer, T. (2013) · Advances in Clinical Chemistry · doi:10.1016/b978-0-12-405211-6.00002-4 · Cited by 12
Association Between Baseline, Achieved, and Reduction of CRP and Cardiovascular Outcomes After LDL Cholesterol Lowering with Statins or Ezetimibe: A Systematic Review and Meta‐Analysis
Zhang, X., Lan, R., Zhang, X., Xu, W., Wang, L., Kang, L., & Xu, B. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012428 · Cited by 15
Time Course of C-Reactive Protein Reduction With Simvastatin Therapy in Patients With Type 2 Diabetes Mellitus
Hernandez, T. L., Capell, W. H., Wolfe, P., Gerard, L., & Eckel, R. H. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.07.047 · Cited by 16
Comparison of Effects of High (80 mg) Versus Low (20 mg) Dose of Simvastatin on C-Reactive Protein and Lipoproteins in Patients With Angiographic Evidence of Coronary Arterial Narrowing
Meredith, K. G., Horne, B. D., Pearson, R. R., Maycock, C. A. A., LAPPE, D. L., Anderson, J. L., & Muhlestein, J. B. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.07.079 · Cited by 16
C-Reactive Protein and Cardiovascular Risk in the Metabolic Syndrome and Type 2 Diabetes: Controversy and Challenge
Capuzzi, D. M., & Freeman, J. S. (2007) · Clinical Diabetes · doi:10.2337/diaclin.25.1.16 · Cited by 17
The Editor's Roundtable: The JUPITER Trial—Initial Results and Clinical Implications
Ridker, P. M., Friedewald, V. E., Davidson, M. H., Willerson, J. T., & Roberts, W. C. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.02.023 · Cited by 16
Self-citation
Inflammation and cardiovascular diseases: lessons that can be learned for the patient with cardiogenic shock in the intensive care unit
Geppert, A., & Huber, K. (2004) · Current Opinion in Critical Care · doi:10.1097/01.ccx.0000139364.53198.fd · Cited by 16
Effect of Bempedoic Acid on atherogenic lipids and inflammation: A meta-analysis
Masson, W. M., Lobo, M., Cobo, A. L., & Molinero, G. B. (2020) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2020.09.002 · Cited by 14
The efficacy of statins in the treatment of rheumatoid arthritis: A systematic review and meta-analysis
Ren, C., & Li, M. (2023) · Medicine · doi:10.1097/md.0000000000035088 · Cited by 17
Short‐Term Treatment with High‐Dose Atorvastatin Reduces LDL Cholesterol but Shows no Anti‐Inflammatory Effects in Normolipidemic Subjects with Normal CRP Levels
Millar, J. S., Ky, B., Wolfe, M. L., Pruscino, L., Baer, A. L., & Rader, D. J. (2010) · Clinical and Translational Science · doi:10.1111/j.1752-8062.2010.00211.x · Cited by 15
The Relationship Between Plasma C-Reactive Protein Levels and Presence and Severity of Coronary Stenosis in Patients With Stable Angina
Uluçay, A., Demirbağ, R., Yılmaz, R., Ünlü, D., Gür, M., Selek, Ş., & Çelık, H. (2007) · Angiology · doi:10.1177/0003319707309118 · Cited by 15
A review of statin use in patients with acute coronary syndrome in Western and Japanese populations
Miyauchi, K., & Ray, K. K. (2013) · Journal of International Medical Research · doi:10.1177/0300060513476428 · Cited by 15
Clinical relevance of peripheral vascular occlusive disease in patients with rheumatoid arthritis and systemic lupus erythematosus 11Competition of interest: none.
Henke, P. K., Sukheepod, P., Proctor, M., Upchurch, G. R., & Stanley, J. C. (2003) · Journal of Vascular Surgery · doi:10.1016/s0741-5214(03)00074-0 · Cited by 15
Risk Stratification and Prognostic Factors in the Post-Myocardial Infarction Patient
Cannon, C. P., & Greenberg, B. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.06.006 · Cited by 15
Statins: Rationale, Mode of Action, and Side Effects
Sultan, S., D'Souza, A., Zabetakis, I., Lordan, R., Τσούπρας, Α., Kavanagh, E. P., & Hynes, N. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813792-5.00006-9 · Cited by 18
Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study
Fonseca, F. A. H., & Izar, M. C. D. O. (2009) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.93 · Cited by 15
Prevention of Positive Coronary Artery Remodeling with Statin Therapy in Patients with Coronary Artery Diseases
Suzuki, M., Saito, M., Nagai, T., Saeki, H., & Kazatani, Y. (2006) · Angiology · doi:10.1177/000331970605700301 · Cited by 15
Clinical Significance of High-Sensitivity C-Reactive Protein in Cardiovascular Disease
Conen, D., & Ridker, P. M. (2007) · Biomarkers in Medicine · doi:10.2217/17520363.1.2.229 · Cited by 16
Self-citation
Inflammation Is a Crucial Feature of Atherosclerosis and a Potential Target to Reduce Cardiovascular Events
Mach, F. (2005) · Handbook of experimental pharmacology · doi:10.1007/3-540-27661-0_26 · Cited by 15
Inflammation in coronary artery disease: potential role for immunomodulatory therapy
Aukrust, P., Yndestad, A., Wæhre, T., Gullestad, L. L., Halvorsen, B. L., & Damås, J. K. (2005) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.3.6.1111 · Cited by 15
Protecting the heart: a practical review of the statin studies.
Ht, O. (2002) · PubMed · Cited by 15
C-Reactive Protein and Atherosclerosis
Kushner, I. (2002) · Science · doi:10.1126/science.297.5581.520 · Cited by 15
New Clinical Markers Predictive of Cardiovascular Disease: The Role of Inflammatory Mediators
Rackley, C. E. (2004) · Cardiology in Review · doi:10.1097/01.crd.0000126083.86717.5b · Cited by 14
Residual Inflammation Indicated by High-Sensitivity C-Reactive Protein Predicts Worse Long-Term Clinical Outcomes in Japanese Patients after Percutaneous Coronary Intervention
Takahashi, N., Dohi, T., Endo, H., Funamizu, T., Wada, H., Doi, S., Kato, Y., Ogita, M., Okai, I., Iwata, H., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041033 · Cited by 14
Novel Systemic Inflammatory Markers Predict All-Cause Mortality in Patients Undergoing Endovascular Abdominal Aortic Aneurysm Repair
Zhao, W.-X., Wu, Z., Zhao, N. O., Diao, Y., Lan, Y., & Li, Y. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2506202 · Cited by 14
Effect of atorvastatin on circulating hsCRP concentrations: A sub-study of the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study
Gensini, G. F., Gori, A. M., Dilaghi, B., Rostagno, C., Gaw, A. J., Blanco‐Colio, L. M., de Teresa, E., Egido, J., Farsang, C., Leiter, L. A., et al. (2009) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.12.213 · Cited by 14
Targeting Inflammation: Impact on Atherothrombosis
Marini, M. G., Sonnino, C., Previtero, M., & Biasucci, L. M. (2013) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-013-9523-7 · Cited by 14
Lipid pharmacotherapy for treatment of atherosclerosis
Nicholls, S. J., Pisaniello, A. D., Kataoka, Y., & Puri, R. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.904287 · Cited by 14
Effects of chromium supplementation on inflammatory biomarkers: A systematic review and dose-response meta-analysis of randomized controlled trials
Sheikhhossein, F., Amini, M. R., Shahinfar, H., Djafari, F., Safabakhsh, M., & Shab‐Bidar, S. (2020) · European Journal of Integrative Medicine · doi:10.1016/j.eujim.2020.101147 · Cited by 14
Changes in C-reactive protein in response to anti-inflammatory therapy as a predictor of cardiovascular outcomes: A systematic review and meta-analysis
Berkley, A., & Ferro, A. (2020) · JRSM Cardiovascular Disease · doi:10.1177/2048004020929235 · Cited by 14
Automatic text-mining as an unbiased approach to uncover molecular associations between periodontitis and coronary artery disease
Trindade, F., Perpétuo, L., Ferreira, R. M., Leite-Moreira, A. F., Falcão‐Pires, I., Guedes, S. D. M., & Vitorino, R. M. P. (2021) · Biomarkers · doi:10.1080/1354750x.2021.1904002 · Cited by 14
Effects of C‐reactive Protein and Homocysteine on Cytokine Production: Modulation by Pravastatin
Asanuma, Y., Oeser, A. M., Stanley, E. M., Bailey, D. G., Shintani, A., & Stein, C. (2008) · Archives of Drug Information · doi:10.1111/j.1753-5174.2007.00003.x · Cited by 14
Cystatin C and long term risk of community-acquired sepsis: a population-based cohort study
Powell, T. C., Donnelly, J. P., Gutiérrez, O. M., Griffin, R. L., Safford, M. M., & Wang, H. E. (2015) · BMC Nephrology · doi:10.1186/s12882-015-0055-z · Cited by 14
Atorvastatin alleviates iodinated contrast media-induced cytotoxicity in human proximal renal tubular epithelial cells
Liu, G.-L., Lei, R., Duan, S.-B., Tang, M., Luo, M., & Xu, Q. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4859 · Cited by 14
Wide-range CRP versus high-sensitivity CRP on Roche analyzers: focus on low-grade inflammation ranges and high-sensitivity cardiac troponin T levels
Monneret, D., Mestari, F., Djiavoudine, S., Bachelot, G., Cloison, M., Imbert‐Bismut, F., Bernard, M., Hausfater, P., Lacorte, J., & Bonnefont‐Rousselot, D. (2018) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2018.1471618 · Cited by 14
A Control-Theoretic Model of Atherosclerosis
Formanowicz, D., Krawczyk, J. B., Perek, B., & Formanowicz, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030785 · Cited by 17
Intraluminal Delivery of Simvastatin Attenuates Intimal Hyperplasia After Arterial Injury
Helkin, A. W., Bruch, D., Wilson, D. R., Gruessner, A. C., Bader, R. A., Maier, K. G., & Gahtan, V. (2019) · Vascular and Endovascular Surgery · doi:10.1177/1538574419833224 · Cited by 14
C-Reactive Protein and Electrocardiographic ST-Segment Depression Additively Predict Mortality
Okin, P. M., Roman, M. J., Best, L. G., Lee, E. T., Galloway, J. M., Howard, B. V., & Devereux, R. B. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.02.072 · Cited by 14
The effect of different doses of fluvastatin on inflammatory markers in the early phase of acute coronary syndrome
Yang, J., Li, X., Zhao, S., Li, J., Li, J., & Xie, X. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2005.12.029 · Cited by 14
Biochemical effects of consumption of eggs containing omega-3 polyunsaturated fatty acids
Öhman, M., Åkerfeldt, T., Nilsson, I., Rosen, C., Hansson, L., Carlsson, M., & Larsson, A. O. (2008) · Upsala Journal of Medical Sciences · doi:10.3109/2000-1967-235 · Cited by 14
Proteína-C-reativa e doença cardiovascular: as bases da evidência científica
Santos, W. B., Mesquita, E. T., Vieira, R. M. R., Olej, B., Coutinho, M. S. S. D. A., & Avezum, Á. (2003) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2003000400010 · Cited by 14
Establishing the benefit of statins in low-to-moderate—risk primary prevention: The Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
Gotto, A. M. (2007) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2007.02.002 · Cited by 14
Self-citation
Statins and the Response to Myocardial Injury
Scalia, R. G. (2005) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200505030-00003 · Cited by 14
Quality specifications and the assessment of the biochemical risk of atherosclerosis
Rifai, N., & Warnick, G. R. (2004) · Clinica Chimica Acta · doi:10.1016/j.cccn.2004.02.034 · Cited by 14
Self-citation
How Do HMG-CoA Reductase Inhibitors Prevent Stroke?
Bedi, A., & Flaker, G. C. (2002) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200202010-00002 · Cited by 14
Atorvastatin lowers plasma low-density lipoprotein cholesterol and C-reactive protein in Japanese type 2 diabetic patients
Yamada, S., Yanagawa, T., Sasamoto, K., Araki, A., Miyao, M., & Yamanouchi, T. (2005) · Metabolism · doi:10.1016/j.metabol.2005.07.017 · Cited by 14
To JUPITER and beyond: Statins, inflammation, and primary prevention
Rao, A. D., & Milbrandt, E. B. (2010) · Critical Care · doi:10.1186/cc9006 · Cited by 13
C-reactive protein for the prediction of cardiovascular risk: Ready for prime-time?
Hackam, D. G. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1031968 · Cited by 13
Effects of ezetimibe/simvastatin 10/10 mg versus Rosuvastatin 10 mg on carotid atherosclerotic plaque inflammation
Oh, M., Kim, H., Shin, E. W., Sung, C., Kim, D.-H., Moon, D. H., & Lee, C. W. (2019) · BMC Cardiovascular Disorders · doi:10.1186/s12872-019-1184-2 · Cited by 13
The Effect of Statins on C‐Reactive Protein in Stroke Patients: A Systematic Review of Clinical Trials
Alikiaii, B., Heidari, Z., Bagherniya, M., Askari, G., Sathyapalan, T., & Sahebkar, A. (2021) · Mediators of Inflammation · doi:10.1155/2021/7104934 · Cited by 13
Rosuvastatin in hemodialysis: short-term effects on lipids and C-reactive protein
Burmeister, J. E., Miltersteiner, D. D. R., & Campos, B. M. (2009) · Journal of Nephrology · doi:10.1093/joneph/22.1.83 · Cited by 13
Effects of Withdrawal of Xuezhikang, an Extract of Cholestin, on Lipid Profile and C-reactive Protein: A Short-Term Time Course Study in Patients with Coronary Artery Disease
Hu, C.-L., Li, Y., Tang, Y., Chen, J.-B., Liu, J., Tang, Q., Zhang, Q., & Huang, C. Y. (2006) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-006-7947-x · Cited by 13
Statins And Biomarkers In Claudicants With Peripheral Arterial Disease: Cross-sectional Study
DePalma, R. G., Hayes, V. W., May, P. E., Cafferata, H. T., Mohammadpour, H. A., Brigg, L. A., Chow, B. K., Shamayeva, G., & Zacharski, L. R. (2006) · Vascular · doi:10.2310/6670.2006.00039 · Cited by 13
A multiple biomarker risk score for guiding clinical decisions using a decision curve approach
Hughes, M., Saarela, O., Blankenberg, S., Zeller, T., Havulinna, A. S., Kuulasmaa, K., Yarnell, J., Schnabel, R. B., Tiret, L., Salomaa, V. V., et al. (2011) · European Journal of Preventive Cardiology · doi:10.1177/1741826711417341 · Cited by 13
Effects of one year simvastatin and atorvastatin treatments on acute phase reactants in uncontrolled type 2 diabetic patients
Ükinç, K., Ersöz, H. Ö., Erem, C., Hacıhasanoğlu, A., & Karti, S. S. (2009) · Endocrine · doi:10.1007/s12020-009-9157-3 · Cited by 13
Coronary artery disease: new insights into the pathophysiology, prevalence, and early detection of a monster menace
Slater, J. N., & Rill, V. (2004) · Seminars in Ultrasound CT and MRI · doi:10.1016/j.sult.2003.11.003 · Cited by 13
Identifying patients at risk of coronary vascular disease: the potential role of inflammatory markers
Kluft, C. (2004) · European Heart Journal Supplements · doi:10.1016/j.ehjsup.2004.04.006 · Cited by 13
Cloning, characterization, expression and comparative analysis of pig Golgi membrane sphingomyelin synthase 1
Guillén, N., Navarro, M. Á., Surra, J. C., Arnal, C., Fernández‐Juan, M., Cebrián-Pérez, J. Á., & Osada, J. (2006) · Gene · doi:10.1016/j.gene.2006.10.013 · Cited by 13
Nitric Oxide, Atherosclerosis and the Clinical Relevance of Endothelial Dysfunction
Anderson, T. J. (2006) · Kluwer Academic Publishers eBooks · doi:10.1007/1-4020-7960-5_5 · Cited by 13
Acute Coronary Syndromes
Hamm, C. W., Möllmann, H., Bassand, J., & de Werf, F. V. (2009) · doi:10.1093/med/9780199566990.003.016 · Cited by 13
Reduction of serum C-reactive protein by statin therapy may reflect decreased isoprenylation of Rac-1, a mediator of the IL-6 signal transduction pathway
McCarty, M. F. (2003) · Medical Hypotheses · doi:10.1016/s0306-9877(02)00232-3 · Cited by 13
Colchicine for cardiovascular and limb risk reduction in Medicare beneficiaries with peripheral artery disease: emulation of target trials
Heindel, P. V., Fitzgibbon, J. J., Secemsky, E. A., Bhatt, D. L., Al-Omran, M. A., Verma, S., AlMaghlouth, I. A., Madenci, A. L., & Hussain, M. A. (2024) · European Heart Journal Open · doi:10.1093/ehjopen/oeae062 · Cited by 13
Role of Sex in Atherosclerosis: Does Sex Matter?
Trivedi, B. S., Desai, R., Mishra, K., Hechanova, L. A., & Abolbashari, M. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01800-7 · Cited by 12
Great debate: lipid-lowering therapies should be guided by vascular imaging rather than by circulating biomarkers
Tokgözoğlu, L. S., Morrow, D. A., & Nicholls, S. J. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad275 · Cited by 12
Statins use and the risk of acute kidney injury: a meta-analysis
Mao, S., & Huang, S. (2014) · Renal Failure · doi:10.3109/0886022x.2014.882715 · Cited by 12
C‐Reactive Protein and the Metabolic Syndrome: Useful Addition to the Cardiovascular Risk Profile?
Szmitko, P. E., & Verma, S. (2006) · Journal of the CardioMetabolic Syndrome · doi:10.1111/j.0197-3118.2006.05340.x · Cited by 12
Lipid lowering efficacy between morning and evening simvastatin treatment: a randomized double-blind study.
Tharavanij, T., Wongtanakarn, S., Lerdvuthisopon, N., Teeraaunkul, S., Youngsriphithak, P., & Sritipsukho, P. (2010) · PubMed · Cited by 12
Pleiotropic effects of statins on acute kidney injury: involvement of Krüppel-like factor 4
Yoshida, T., & Hayashi, M. (2016) · Clinical and Experimental Nephrology · doi:10.1007/s10157-016-1286-4 · Cited by 11
An Aggregate Biomarker Risk Score Predicts High Risk of Near‐Term Myocardial Infarction and Death: Findings From BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes)
Ghasemzadeh, N., Brooks, M. M., Vlachos, H. A., Hardison, R. M., Sikora, S., Sperling, L. S., Quyyumi, A. A., & Epstein, S. E. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.003587 · Cited by 12
Artérite de Takayasu et athérosclérose
Hatri, A., Guermaz, R., Laroche, J.-P., Zekri, S., & Brouri, M. (2019) · JMV-Journal de Médecine Vasculaire · doi:10.1016/j.jdmv.2019.07.002 · Cited by 12
Evaluation of C-Reactive Protein in Primary and Secondary Prevention
Corrado, E., & Novo, S. (2007) · Journal of Investigative Medicine · doi:10.2310/6650.2007.00023 · Cited by 12
Pharmacoepidemiology and disability in older adults: can medications slow the age-related decline in physical function?
Savo, A., Maiorano, P. M., Onder, G., & Bernabei, R. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.2.407 · Cited by 12
A Simple Biomarker to Exclude the Presence of Low Grade Inflammation in Apparently Healthy Individuals
Berliner, S. A., Zeltser, D., Shapira, I., Assayag, E. B., Mardi, T., Serov, J., Aharonov, S., Arber, N., & Rotstein, R. (2002) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/174182670200900509 · Cited by 12
Statins Do Not Reduce Atrial Fibrillation After Cardiac Valvular Surgery: A Single Centre Observational Study
Folkeringa, R., Tieleman, R. G., Maessen, J. G., Prins, M. H., Nieuwlaat, R., & Crijns, H. J. G. M. (2010) · Netherlands Heart Journal · doi:10.1007/s12471-010-0055-3 · Cited by 12
Lower Extremity Arterial Reconstruction in Patients With Diabetes Mellitus
Hughes, K., Campbell, D. R., & Pomposelli, F. B. (2006) · Humana Press eBooks · doi:10.1007/978-1-59745-075-1_22 · Cited by 12
Arteries, inflammation and insulin resistance
Amar, J., Perez, L., Burcelin, R., & Chamontin, B. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000240042.50838.61 · Cited by 12
Highly sensitive determination of C-reactive protein on the Innotrac Aio! immunoanalyzer
Hedberg, P., Ylitalo, K. V., & Puukka, M. (2004) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365510410002931 · Cited by 12
C-Reactive Protein and Asymmetric Dimethylarginine: Markers or Mediators in Cardiovascular Disorders?
Smith, C. L. (2007) · Current Pharmaceutical Design · doi:10.2174/138161207780831338 · Cited by 12
C-reactive protein and cardiovascular risk: an update on what is going on in cardiology
Köenig, W. (2003) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg103 · Cited by 12
New and Emerging Strategies for Reducing Cardiometabolic Risk Factors
Rodgers, P. T., & Fuke, D. C. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.5part2.13s · Cited by 12
Will Reducing Inflammation Reduce Vascular Event Rates?
Ridker, P. M., & Narula, J. (2017) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2017.10.001 · Cited by 13
Self-citation
Atherosclerosis and lipoprotein metabolism
Rang, H. P., Dale, M. M., Ritter, J., & Flower, R. J. (2007) · Elsevier eBooks · doi:10.1016/b978-0-443-06911-6.50025-6 · Cited by 10
Importance of Intermittent Fasting Regimens and Selection of Adequate Therapy on Inflammation and Oxidative Stress in SARS-CoV-2 Infection
Ezzati, A., Rosenkranz, S. K., & Horne, B. D. (2022) · Nutrients · doi:10.3390/nu14204299 · Cited by 11
The Effect of Rosuvastatin on Inflammation, Matrix Turnover and Left Ventricular Remodeling in Dilated Cardiomyopathy: A Randomized, Controlled Trial
Broch, K., Askevold, E. T., Gjertsen, E., Ueland, T., Yndestad, A., Godang, K., Stueflotten, W., Andreassen, J., Svendsmark, R., Smith, H., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089732 · Cited by 11
Management of Cardiovascular Disease in the Renal Transplant Recipient
Rigatto, C. (2005) · Cardiology Clinics · doi:10.1016/j.ccl.2005.03.008 · Cited by 11
Changes of High Sensitivity C-Reactive Protein During Clopidogrel Therapy in Patients Undergoing Percutaneous Coronary Intervention
Hajsadeghi, S., Chitsazan, M., Chitsazan, M., Salehi, N., Amin, A., Maleki, M., Babaali, N., Abdi, S., & Mohsenian, M. (2015) · Research in Cardiovascular Medicine · doi:10.5812/cardiovascmed.28997 · Cited by 11
Atherosklerose als inflammatorische Erkrankung – Pathophysiologie, klinische Relevanz und therapeutische Implikationen
Arnold, N., & Köenig, W. (2019) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-0657-1595 · Cited by 11
Prediction and early detection of cardiovascular disease in South Asians with diabetes mellitus
Wander, G. S., Bansal, M., & Kasliwal, R. R. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.04.017 · Cited by 12
Reduction in hsCRP levels is associated with decreased incidence of cardiovascular events in Japanese hypertensive women but not in men
Kim‐Mitsuyama, S., Soejima, H., Yasuda, O., Node, K., Jinnouchi, H., Yamamoto, E., Sekigami, T., Ogawa, H., & Matsui, K. (2020) · Scientific Reports · doi:10.1038/s41598-020-73905-4 · Cited by 12

Authors: Ridker, P. M., Rifai, N., Clearfield, M., Downs, J. R., Weis, S. E., Miles, J. S., & Gotto, A. M.
Affiliations: Brigham and Women's Hospital (US)
University of North Texas Health Science Center (US)
Wilford Hall Ambulatory Surgical Center (US)
ORCID: Ridker, Paul M.
Rifai, Nader
Weis, Stephen E.
Gotto, Antonio M.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2001-06-28
Volume: 344
Issue: 26
Pages: 1959-1965
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm200106283442601
OpenAlex: W2316243284
Cited by: 1,557
References: 27
Citations by year: 2026: 12 · 2025: 19 · 2024: 16 · 2023: 29 · 2022: 34 · 2021: 30 · 2020: 35 · 2019: 38 · 2018: 29 · 2017: 25 · 2016: 39 · 2015: 41 · 2014: 39 · 2013: 43 · 2012: 52
FWCI: 158.00
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: Doris Duke Charitable Foundation
American Heart Association
Fondation Leducq
National Heart, Lung, and Blood Institute (R01HL058755, HL-58755)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Keywords: C-reactive protein, statin therapy, lovastatin, primary prevention, acute coronary events, cardiovascular risk stratification, TC/HDL-C ratio, hyperlipidemia, inflammation, number needed to treat
MeSH terms: Acute Disease, Anticholesteremic Agents, C-Reactive Protein, Cholesterol, Coronary Disease, Double-Blind Method, Follow-Up Studies, Humans, Cholesterol, HDL, Lovastatin, Primary Prevention, Risk, Risk Factors, Proportional Hazards Models, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks